Retracted 1977 Lancet Talc Commentary

"Cosmetic talc powder" (The Lancet, 1977)
Published	The Lancet, 25 June 1977, volume 1, issue 8026, pages 1348-1349
Byline	None (unsigned commentary)
Author, as identified in 2026	Francis J.C. Roe, cancer researcher and consultant (died 2007)
Retracted	Online 25 March 2026; in print 4 April 2026
Reason given	Undeclared competing interest with Johnson & Johnson
Raised by	Historians David Rosner and Gerald Markowitz
Follow-up study	American Journal of Public Health, online 1 October 2026

Executive Summary

"Cosmetic talc powder" was an unsigned commentary published by The Lancet on 25 June 1977 and retracted by the journal in March 2026. In the account of historians Gerald Markowitz and David Rosner, it asserted that there was no need for regulation because the cosmetic industries in the United States and Britain had made sure their products were virtually free of asbestos fibers. It appeared while the U.S. Food and Drug Administration (FDA) was considering regulatory testing of cosmetic talc for asbestos.

The commentary carried no byline. In 2026 the historians showed that it had been written by Francis J.C. Roe, a consultant to Johnson & Johnson. The Lancet's editors called Roe's undisclosed conflict of interest "a clear breach of publishing ethics" and said they would not have published the piece had the editors at the time known of it. The retraction concerns authorship and disclosure. It is not a new scientific finding about talc or asbestos, and it does not decide whether any person's illness was caused by any product.

A paper published on 1 October 2026 in the American Journal of Public Health added a further finding: Johnson & Johnson persuaded a nonprofit scientific organization to remove a warning from its Talc Monograph, in part by citing the Lancet commentary. The historians who brought the documents to light have served as witnesses for people who developed diseases from asbestos products, including talc, a role readers should weigh.

At-a-Glance

The 1977 Lancet talc commentary at a glance:

• Published 25 June 1977 — an unsigned piece titled "Cosmetic talc powder" in The Lancet, volume 1, issue 8026
• Its argument — no regulation was needed because cosmetic talc in the United States and Britain was virtually free of asbestos fibers, as the AJPH authors summarize it
• The context — the FDA had first tried to regulate asbestos in talc in 1973
• The author — Francis J.C. Roe, identified in 2026 as a consultant to Johnson & Johnson
• Pre-publication contact — a 1977 letter from Roe to Johnson & Johnson's director of medical affairs said he had "met your two points"
• Retracted 25 March 2026 — The Lancet published the retraction notice online, then in its 4 April 2026 issue
• The editors' finding — Roe's conflict of interest was "a clear breach of publishing ethics"
• A second use — Johnson & Johnson cited the commentary, in part, to have a warning removed from a nonprofit's Talc Monograph
• 49 years — the gap between publication and retraction, among the five longest Retraction Watch has recorded
• What it is not — a toxicology study, or a ruling on any individual's illness

Key Facts

Measure	Finding (Source)
Original publication	25 June 1977 — Lancet 1(8026):1348-1349, as recorded in PubMed's entry for the 2026 retraction notice
Byline	None — an unsigned commentary, per the AJPH authors
Author identified	Francis J.C. Roe — Retraction Watch, 25 March 2026
Historians contact The Lancet	8 December 2025 — Retraction Watch, 2026
Published letter	Lancet 407(10536):1328-1330 — Rosner and Markowitz, 2026
Editors' reply	Lancet 407(10536):1330 — The Editors of The Lancet, 2026
Retraction notice	Lancet 407(10536):1315 — online 25 March 2026
Roe's 1979 Lancet letter	Lancet 1979;2(8145):744 — "Controversy: cosmetic talc and ovarian cancer"
Follow-up history	Am J Public Health, 1 October 2026 — Markowitz and Rosner, pages e1-e4
Talc Monograph	Warning removed — after Johnson & Johnson cited the commentary, per the AJPH authors

What Did the 1977 Commentary Say?

The piece ran in The Lancet's issue of 25 June 1977 under the title "Cosmetic talc powder." It carried no byline; the AJPH authors describe it as an unsigned commentary. Unsigned pieces of this kind were routine for the journal at the time. In their 2026 reply, the editors said publishing unsigned commentaries "used to be standard practice."

According to Markowitz and Rosner, the commentary asserted that there was no need for regulation because the cosmetic industries in the United States and Britain had made sure their products were virtually free of asbestos fibers. Johnson & Johnson called it an "editorial." Retraction Watch described it as an argument against government-mandated regulatory testing for asbestos in cosmetic talc.

Its weight came from where it appeared. The AJPH authors write that the industry's claim that asbestos in talc was not a danger gained legitimacy when The Lancet, which they call perhaps the world's leading medical journal, published the commentary.

That reading lasted for decades. Rosner told Retraction Watch that he and Markowitz had been "confronted by attorneys for talc products" with the 1977 piece four or five times in recent years, and that defense attorneys "used it to basically say that the medical field did not consider asbestos in talc dangerous."

What Was the Regulatory Background?

The commentary appeared during a regulatory dispute that was already four years old. According to the AJPH paper, the FDA first tried to regulate asbestos in talc in 1973, provoking a vigorous response from the cosmetics industry, which used talc in a variety of body, baby and bath powders as well as cosmetics.

Retraction Watch reports that the FDA was considering regulatory monitoring of cosmetic talc for asbestos around the time the commentary was published, and that the task ultimately became the responsibility of cosmetics companies. Testing was left to the industry rather than written into federal rules.

The question returned in the 2020s. In December 2024 the FDA proposed "to require testing of talc-containing cosmetic products using standardized testing methods for detecting and identifying asbestos that may be present as a contaminant in talc." In November 2025 it withdrew that proposal, stating that it was taking the action "in response to comments received during the comment period for the proposed rule that warrant further consideration and assessment prior to issuing final regulations." The withdrawal notice also said the agency would issue a new proposed rule to meet its obligations under section 3505 of the Modernization of Cosmetics Regulation Act of 2022. The regulatory history is set out in detail at FDA and EPA Regulations on Talc Asbestos Testing.

In the letter they published in The Lancet, Rosner and Markowitz wrote that the 2024 proposal "would have been a major advance in the nearly half-century effort to eliminate a key source of asbestos-related disease affecting generations," as Retraction Watch reported it.

Who Wrote It, and How Was That Established?

Retraction Watch identified the author as Francis J.C. Roe, a cancer researcher who worked for Royal Marsden Hospital and the Tobacco Research Council but spent most of his career as an independent consultant. Roe died in 2007. The AJPH paper describes the author as a consultant to Johnson & Johnson.

Rosner told Retraction Watch that the two historians have amassed millions of documents collected during discovery processes, and that a few months before the March 2026 retraction they discovered the 1977 article had been written by Roe. Retraction Watch reports that the paper trail was published as a supplement to the historians' letter in The Lancet.

The central document is a 1977 letter from Roe to Gavin Hildick-Smith, then director of medical affairs at Johnson & Johnson. In it, Roe wrote that he had "taken into account your two points on the original … in a slightly different way from that proposed by yourself – But I think I have met your two points." Rosner and Markowitz read the letter as showing that Roe shared the article with the company and sought its input before publication.

Roe did not stay entirely silent about his industry ties. In a letter to The Lancet published in October 1979, titled "Controversy: cosmetic talc and ovarian cancer," he referred to his own then-anonymous 1977 article as "balanced" and disclosed that he was a consultant to the Cosmetic Toiletry and Perfumery Association. That letter did not identify him as the author of the 1977 piece.

Why Did The Lancet Retract It?

Rosner and Markowitz contacted The Lancet about the documents on 8 December 2025. On 25 March 2026 the journal published three items together: the historians' letter, "Asbestos, talc, and The Lancet's 1977 publication"; the editors' reply; and a retraction notice for the 1977 commentary. All three appear in the journal's 4 April 2026 issue.

In their reply, as quoted by Retraction Watch, the editors wrote: "Roe's conflict of interest with Johnson & Johnson was a clear breach of publishing ethics." They added: "In our view, had the editors at the time known of this situation and been aware of the author's undeclared competing interest, they would not have published this commentary."

A Lancet representative told Retraction Watch that the journal would now consider an unsigned letter only "in rare circumstances where there are concerns about author safety," and that the editors would still know the author's name and affiliation. The AJPH paper states the sequence in the authors' own words: the editors retracted the nearly 50-year-old unsigned publication after the historians alerted them through correspondence that it had been written by a consultant to Johnson & Johnson.

The 49 years between publication and retraction is not a record, but Retraction Watch places it among the top five gaps it has recorded.

What Does the 2026 AJPH Paper Add?

On 1 October 2026 the American Journal of Public Health published "Allaying 'Anxieties in Government Officials, Physicians and the Public': Johnson & Johnson and The Lancet Editorial of 1977," by Markowitz and Rosner. The paper places the commentary inside the longer regulatory history, from the FDA's 1973 attempt to regulate asbestos in talc to the 2026 retraction.

Its new finding concerns a second use of the commentary. The authors report that Johnson & Johnson succeeded in persuading a nonprofit scientific organization to remove a warning from its Talc Monograph, in part by citing The Lancet editorial. In the authors' account, the commentary was used to change another institution's safety document, not only to argue against regulation.

The paper's abstract does not name the organization or give the date the warning was removed. This page does not name either until a source we have read states them.

What Are the Limits and Disputed Points?

The retraction is about disclosure, not toxicology. The editors' stated reason is the author's undeclared competing interest. The retraction does not test any talc product, and it does not establish that talc caused any individual's disease. The National Cancer Institute states that "the major risk factor for mesothelioma is asbestos exposure." In any talc case, the questions are whether a particular product contained asbestos and whether the person was exposed to it. The retraction does not answer either question.

The historians have a role in litigation. Rosner and Markowitz have served as witnesses on behalf of people who developed diseases from exposure to asbestos products, including talc. Product-litigation attorney Nathan Schachtman told Retraction Watch they are "big-time testifiers for the plaintiffs' bar," and said a 50-year-old unsigned editorial "would not be relied upon to any significant degree" in court. The Lancet's editors retracted the commentary after the historians' correspondence.

Johnson & Johnson disputes the characterization. A company representative told Retraction Watch that Johnson & Johnson "strongly disagrees with the suggestion that a 1977 editorial in The Lancet reflects misconduct or warrants retroactive condemnation," and said "the journal is being used as part of ongoing and underhanded litigation tactics." The statement said the effort comes at the cost of besmirching Roe's good name.

Roe cannot respond. He died in 2007, nearly two decades before the authorship was established.

What this page could not read. The Lancet's own pages for the retraction notice, the historians' letter and the editors' reply did not load in our tools, and the full AJPH paper sits behind a paywall. Where this page quotes the editors or the historians' letter, it quotes them as Retraction Watch reported them. We did not read the text of the 1977 commentary itself; its argument is described here as the AJPH authors and Retraction Watch describe it. This page cites the retracted commentary only as its subject, for its bibliographic record (PubMed 69063, which carries PubMed's "Retracted Publication" tag), never as a source for any claim; its date, volume and pages also match PubMed's entry for the 2026 retraction notice, and bibliographic details for every other Lancet item come from PubMed's index records.

Frequently Asked Questions

What was the 1977 Lancet talc commentary?

It was an unsigned piece titled "Cosmetic talc powder," published in The Lancet on 25 June 1977. According to historians Gerald Markowitz and David Rosner, it asserted that regulation was unnecessary because cosmetic talc in the United States and Britain was virtually free of asbestos fibers.

Who wrote it?

Francis J.C. Roe, a cancer researcher and consultant who died in 2007, according to Retraction Watch's March 2026 report. The AJPH paper describes the author as a consultant to Johnson & Johnson.

Why did The Lancet retract it?

The editors said Roe's conflict of interest with Johnson & Johnson was a clear breach of publishing ethics, and that they would not have published the piece had the editors at the time known of his undeclared competing interest. The retraction notice was published online on 25 March 2026.

What did the 2026 AJPH paper find?

It reports that Johnson & Johnson persuaded a nonprofit scientific organization to remove a warning from its Talc Monograph, in part by citing the Lancet commentary. The abstract does not name the organization.

Does the retraction prove that cosmetic talc causes mesothelioma?

No. The retraction concerns who wrote the commentary and what the author failed to disclose. It does not test any product or decide whether any person's illness came from talc. The major risk factor for mesothelioma is asbestos exposure, according to the National Cancer Institute.

Did Johnson & Johnson respond?

Yes. A company representative told Retraction Watch that Johnson & Johnson strongly disagrees with the suggestion that the editorial reflects misconduct or warrants retroactive condemnation, and called the effort part of "ongoing and underhanded litigation tactics."

Do the historians have a stake in talc litigation?

Retraction Watch reports that Rosner and Markowitz have served as witnesses on behalf of people who developed diseases from exposure to asbestos products, including talc, and that they have amassed millions of documents collected during discovery processes.

Quick Statistics

• 1973 — the year the FDA first tried to regulate asbestos in talc
• 25 June 1977 — publication of the unsigned commentary
• 1979 — Roe's Lancet letter disclosing his consultancy to the Cosmetic Toiletry and Perfumery Association
• 2007 — Roe's death
• 8 December 2025 — the historians contacted The Lancet
• 25 March 2026 — retraction notice published online
• 49 years — publication to retraction
• 1 October 2026 — the AJPH follow-up paper published online

External Links

• Mesothelioma Lawyers Near Me — The Lancet's Retracted 1977 Talc Commentary — news brief on the AJPH paper and the retraction
• Danziger & De Llano — national mesothelioma and asbestos-injury law firm
• Mesothelioma Lawyer Center — company and product histories

Related Pages

• FDA and EPA Regulations on Talc Asbestos Testing — the federal regulatory history of asbestos testing in talc
• WHO IARC Talc Probably Carcinogenic Group 2A — the IARC carcinogenicity classification of talc
• Talc Miners — occupational asbestos exposure in talc mining and milling
• Asbestos in Consumer Products — asbestos contamination across consumer goods
• Mesothelioma — the cancer most closely associated with asbestos exposure